Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differences between patients’ genetic makeup and the effect this has on drug response, pharmacogenomics has the potential to reduce medical costs, improve drug development and therapy and cause a shift from treatment to prevention.
This report coincides with the completion of the map of the genome and the development of new technologies developed following this breakthrough.
Benefiting from a survey of over 50 executives in leading pharmaceutical and pharmacogenomics companies, this report provides a unique insight into the current state and future direction of the pharmacogenomics market over the next ten years. It looks at the key industry drivers, identifies important strategic possibilities and potential for collaboration.
